Validation of Mesoscopic Imaging to Predict Cutaneous Carcinogenesis and its Therapeutic Response

验证细观成像预测皮肤癌发生及其治疗反应

基本信息

  • 批准号:
    10595503
  • 负责人:
  • 金额:
    --
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-10-01 至 2023-09-30
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY Actinic neoplasia (precancerous actinic keratosis and non-melanoma skin cancer) is the most common type of human neoplasia, and the most common diagnosis in VA dermatology clinics. We and other groups have characterized the mechanisms by which aging and ultraviolet B radiation (UVB) contribute to actinic neoplasia. In particular, human skin at high risk for actinic neoplasia exhibits biochemical features, including decreased keratinocyte expression of DNA repair enzymes, increased numbers of senescent fibroblasts with lower levels of fibroblast IGF-1, and increased fibroblast cytokines including IL-6, IL-8 and TNF. Moreover, at risk skin responds to UVB by generating basal keratinocytes proliferating while still harboring DNA mutations. This revised VA Merit application will leverage our recent findings that a noninvasive, multi-spectral, mesoscopic imaging platform could potentially identify clinically normal-appearing skin at risk for actinic neoplasia. This proposal also provides evidence that mesoscopic imaging could have use in quantifying field carcinogenesis. To that end, two specific aims will test the hypothesis that mesoscopic imaging will be able to discern skin with biochemical and functional characteristics of tissue at high risk for actinic neoplasia. The first aim consists of two parts. In the first part, mesoscopic imaging will be used to predict areas of at-risk vs. normal skin, which will be tested with biopsies and non-invasive transcriptome analysis to compare imaging parameter-based predictions against biochemical, histological and functional features associated with skin at high risk for actinic neoplasia. In the second part of Aim 1 we will take advantage of our recent findings that wounding of photo- damaged geriatric skin with fractionated laser resurfacing normalizes the actinic neoplastic biochemical/histological changes. We will leverage these findings by conducting mesoscopic imaging of laser- wounded vs unwounded skin in geriatric subjects with photo-damaged skin. The second aim will test the ability of mesoscopic imaging to quantify the effectiveness of topical photodynamic therapy (PDT) performed or chemotherapy agent 5-fluorouracil cream on subjects with multiple actinic keratosis requiring field therapy. Additionally, subjects at high risk for actinic neoplasia not treated with field therapy will be monitored longitudinally in clinics by serial mesoscopic imaging. These three strategies in Aim 2 will test if this noninvasive imaging can predict where actinic keratosis will arise and assess if mesoscopic imaging has use in the clinic for quantifying skin at-risk for actinic neoplasia and actinic keratosis. The overall goal is to establish a fast, wide- field, multi-spectral imaging system that can provide quantitative imaging parameters for monitoring human skin non-invasively. If successful, these studies will validate a valuable clinical tool that can stratify risk of actinic neoplasia even when skin appears clinically normal. Moreover, this non-invasive, image-based contrast mapping approach could serve to propel research in field cancerization using skin as a model system, which could be adapted to other organ systems such as colon, esophagus and lung cancers. These studies will improve the care of veterans served in our dermatology clinics. This proposal will also provide valuable tools for both the study and monitoring of many cancer types found in US Veterans.
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jeffrey B. Travers其他文献

Relevance of the Platelet-activating factor system in chemical warfare agents-induced effects
血小板活化因子系统在化学战剂诱导效应中的相关性
  • DOI:
    10.1016/j.freeradbiomed.2024.12.037
  • 发表时间:
    2025-02-16
  • 期刊:
  • 影响因子:
    8.200
  • 作者:
    Anita Thyagarajan;Jeffrey B. Travers;Ravi P. Sahu
  • 通讯作者:
    Ravi P. Sahu
Topical Photodynamic Therapy Generates Bioactive Microvesicle Particles: Evidence for a Pathway Involved in Immunosuppressive Effects
局部光动力疗法产生生物活性微泡颗粒:参与免疫抑制作用途径的证据
  • DOI:
    10.1016/j.jid.2022.12.018
  • 发表时间:
    2023-07-01
  • 期刊:
  • 影响因子:
    5.700
  • 作者:
    Oladayo A. Oyebanji;Chad Brewer;Sharlo Bayless;Benjamin Schmeusser;Danielle A. Corbin;Courtney E.W. Sulentic;Catherine M.T. Sherwin;Yanfang Chen;Christine M. Rapp;Elizabeth E. Cates;Yuhan Long;Jeffrey B. Travers;Craig A. Rohan
  • 通讯作者:
    Craig A. Rohan
Case Studies of Sustained Remission of Membranous Glomerulonephritis With Dupilumab Treatment
  • DOI:
    10.1016/j.ekir.2024.09.024
  • 发表时间:
    2024-12-01
  • 期刊:
  • 影响因子:
  • 作者:
    Mark H. Kaplan;Jessica M. Greco;Brad H. Rovin;Anthony M. Cannon;Abigail Pajulas;Jeffrey B. Travers;Ayman Hallab;Matthew J. Turner
  • 通讯作者:
    Matthew J. Turner
Toxic cutaneous responses from inhalant abuse
  • DOI:
    10.1016/j.jdcr.2018.10.009
  • 发表时间:
    2019-01-01
  • 期刊:
  • 影响因子:
  • 作者:
    Ahmed Hawash;Jeffrey B. Travers;Sibel Gokce
  • 通讯作者:
    Sibel Gokce
Lymphocyte activation in the pathogenesis of psoriasis.
银屑病发病机制中的淋巴细胞活化。
  • DOI:
  • 发表时间:
    1997
  • 期刊:
  • 影响因子:
    6.5
  • 作者:
    David A. Norris;Jeffrey B. Travers;Donald Y.M. Leung
  • 通讯作者:
    Donald Y.M. Leung

Jeffrey B. Travers的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jeffrey B. Travers', 18)}}的其他基金

Validation of Mesoscopic Imaging to Predict Cutaneous Carcinogenesis and its Therapeutic Response
验证细观成像预测皮肤癌发生及其治疗反应
  • 批准号:
    10295161
  • 财政年份:
    2019
  • 资助金额:
    --
  • 项目类别:
Validation of Mesoscopic Imaging to Predict Cutaneous Carcinogenesis and its Therapeutic Response
验证细观成像预测皮肤癌发生及其治疗反应
  • 批准号:
    10041690
  • 财政年份:
    2019
  • 资助金额:
    --
  • 项目类别:
IGF-1 and the initiation of non-melanoma skin cancer
IGF-1 与非黑色素瘤皮肤癌的发生
  • 批准号:
    8967172
  • 财政年份:
    2014
  • 资助金额:
    --
  • 项目类别:
IGF-1 and the initiation of non-melanoma skin cancer
IGF-1 与非黑色素瘤皮肤癌的发生
  • 批准号:
    8539867
  • 财政年份:
    2014
  • 资助金额:
    --
  • 项目类别:
IGF-1 and the initiation of non-melanoma skin cancer
IGF-1 与非黑色素瘤皮肤癌的发生
  • 批准号:
    8892803
  • 财政年份:
    2014
  • 资助金额:
    --
  • 项目类别:
IGF-1 and the initiation of non-melanoma skin cancer
IGF-1 与非黑色素瘤皮肤癌的发生
  • 批准号:
    9242476
  • 财政年份:
    2014
  • 资助金额:
    --
  • 项目类别:
The Indiana Cutaneous Biological Research Training Program
印第安纳州皮肤生物学研究培训计划
  • 批准号:
    8473519
  • 财政年份:
    2013
  • 资助金额:
    --
  • 项目类别:
Oxidized lipids and UV immunosuppression
氧化脂质和紫外线免疫抑制
  • 批准号:
    8391609
  • 财政年份:
    2010
  • 资助金额:
    --
  • 项目类别:
Oxidized lipids and UV immunosuppression
氧化脂质和紫外线免疫抑制
  • 批准号:
    8597389
  • 财政年份:
    2010
  • 资助金额:
    --
  • 项目类别:
Oxidized lipids and UV immunosuppression
氧化脂质和紫外线免疫抑制
  • 批准号:
    8762399
  • 财政年份:
    2010
  • 资助金额:
    --
  • 项目类别:

相似海外基金

Understanding age at first autism health claim and acute health service use in girls and women relative to boys and men
了解女孩和女性相对于男孩和男性的首次自闭症健康声明和紧急医疗服务使用情况
  • 批准号:
    419977
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
    Operating Grants
Proposal of a model plan for a high-activity operating department in an acute care hospital based on long-term PDCA in the age of minimally invasive treatment
微创治疗时代基于长期PDCA的急症医院高活动手术科室模型方案提出
  • 批准号:
    18K04486
  • 财政年份:
    2018
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Study of pathogenic mechanism of age-dependent chromosome translocation in adult acute lymphoblastic leukemia
成人急性淋巴细胞白血病年龄依赖性染色体易位发病机制研究
  • 批准号:
    18K16103
  • 财政年份:
    2018
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
ISCHAEMIC ACUTE RENAL FAILURE AND AGE: MODULATION BY ANTI-INFLAMMATORY EMBRYONIC STEM CELL-DERIVED MACROPHAGES
缺血性急性肾衰竭和年龄:抗炎胚胎干细胞源性巨噬细胞的调节
  • 批准号:
    G0801235/1
  • 财政年份:
    2009
  • 资助金额:
    --
  • 项目类别:
    Research Grant
AGE-RELATED DIFFERENCES IN ENERGY EXPENDITURE IN RESPONSE TO ACUTE EXERCISE
剧烈运动时的能量消耗与年龄相关的差异
  • 批准号:
    7951393
  • 财政年份:
    2009
  • 资助金额:
    --
  • 项目类别:
Age factors, mutations, and chemical suppressors of acute myelogenous leukemia
急性髓性白血病的年龄因素、突变和化学抑制剂
  • 批准号:
    8306217
  • 财政年份:
    2008
  • 资助金额:
    --
  • 项目类别:
Age-related differences in the acute thermoregulatory responses to cold
对寒冷的急性体温调节反应与年龄相关的差异
  • 批准号:
    347633-2008
  • 财政年份:
    2008
  • 资助金额:
    --
  • 项目类别:
    Postgraduate Scholarships - Master's
Age factors, mutations, and chemical suppressors of acute myelogenous leukemia
急性髓性白血病的年龄因素、突变和化学抑制剂
  • 批准号:
    7530462
  • 财政年份:
    2008
  • 资助金额:
    --
  • 项目类别:
Acute and chronic GPCR Medicated Cardioprotection: Roles of receptor Cross-Talk, Cellular signaling, and effects of Age
急性和慢性 GPCR 药物心脏保护:受体串扰的作用、细胞信号传导以及年龄的影响
  • 批准号:
    nhmrc : 428251
  • 财政年份:
    2008
  • 资助金额:
    --
  • 项目类别:
    Career Development Fellowships
Age factors, mutations, and chemical suppressors of acute myelogenous leukemia
急性髓性白血病的年龄因素、突变和化学抑制剂
  • 批准号:
    8134266
  • 财政年份:
    2008
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了